

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI791375

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	Confirmatory Assignment
RESUBMIT DOCUMENT ID:	508945944
CONVEYING PARTY DATA	
Name	Execution Date
Neotope Neuroscience Limited	12/22/2021
RECEIVING PARTY DATA	
Company Name:	Novo Nordisk A/S
Street Address:	Novo Alle' 1
City:	Bagsvaerd
State/Country:	DENMARK
Postal Code:	2880
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16753307
CORRESPONDENCE DATA	
Fax Number:	7044441111
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9198622292
Email:	keisha.preddie@alston.com,susan.sather@alston.com
Correspondent Name:	LaKeisha Preddie
Address Line 1:	Alston & Bird LLP
Address Line 2:	Vantage South End 1120 South Tryon Street Suite 300
Address Line 4:	Charlotte, NORTH CAROLINA 28203-6818
ATTORNEY DOCKET NUMBER:	044182/542009
NAME OF SUBMITTER:	LaKeisha Robinson Preddie
SIGNATURE:	/LaKeisha Robinson Preddie/
DATE SIGNED:	01/30/2025
Total Attachments: 3	
source=3519_001#page1.tiff	
source=3519_001#page2.tiff	
source=3519_001#page3.tiff	

CONFIRMATORY ASSIGNMENT

WHEREAS NEOTOPE NEUROSCIENCE LIMITED is a private limited company incorporated under the laws of Ireland, formerly having its registered office at 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland, and currently having its registered office at c/o Novo Nordisk Limited, First Floor, Block A, The Crescent Building, Northwood Business Park, Dublin, Ireland ("Assignor");

WHEREAS, NOVO NORDISK A/S is a publicly-traded corporation incorporated under the laws of Denmark, and having its registered office at Novo Alle' 1, 2880 Bagsvaerd, Denmark ("Assignee");

WHEREAS pursuant to the Asset Transfer Agreement between Assignor and Assignee of December 22, 2021, Assignor has agreed to assign and has assigned the entire right title and interest in the patent filings identified on the attached Schedule A, the inventions described therein and all corresponding patent filings worldwide to Assignee;

NOW, THEREFORE, to confirm, supplement and insofar as relevant supplant the Asset Transfer Agreement between Assignor and Assignee of December 22, 2021, and the good and sufficient consideration set forth therein, the receipt of which is hereby acknowledged, Assignor has assigned, and by these presents does assign to Assignee, all of Assignor's right, title, and interest in the patent filings identified on Schedule A, the inventions described therein, any right to claim priority therefrom, any patents to result from the same, and any continuation, divisional, continuation-in-part, reissue or other application or patent claiming priority thereto in any country throughout the world as fully and entirely as the same would have been held by Assignor had this assignment not have been made;

To the extent allowed by law this assignment to be effective as of December 22, 2021;

IN TESTIMONY WHEREOF, duly authorized representatives of Assignor and Assignee have signed on the date indicated.

Date: 17 December 2024

NEOTOPE NEUROSCIENCE LIMITED

By: 


Printed Name: DAVID SCOTT

Title: ATTORNEY

Notarization Preferred

Date: 28 - Nov - 2024

NOVO NORDISK A/S
By: _____



Printed Name:
Title:

Lars Keilberg
Corporate Vice President
Corporate Patents
Novo Nordisk A/S

Notarization Preferred

SCHEDULE A

A&B Matter No.	Novo Nordisk A/S Ref. No.	Country	Application No.	Filing Date	Publication No.	Patent No.	Issue Date
044182/542009	220137US03	UNITED STATES	16/753,307	04/02/2020	2020-0331992	11.267,877	03/08/2022
044182/541985	220139US02	UNITED STATES	16/767,994	05/28/2020	2020-0362023		
044182/542797	220138US04	UNITED STATES	16/753,661	04/03/2020	2020-0249244		

LEGAL02/43220530v1